Figure 2.

Intratumoral injection of VV-scFv-TIGIT enhanced antitumor efficacy in subcutaneous (S.C.) tumor models. (A) The S.C. tumor models of 4T1, CT26, and H22 were established by inoculation of corresponding cells on the right flank of BALB/c mice. Seven days after tumor inoculation, mice were administered intratumorally (I.T.) with the indicated VV or PBS. (B) MC38 S.C. tumor model was similarly established on C57BL/6 mice and injected intratumorally with the indicated VV or PBS 5 days after the tumor inoculation. Tumor volume and body weight were measured every 2 days. Error bars represent SD. Once the tumor volume exceeded 2000 mm³, the mouse was considered dead. ns, no significant differences; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. PBS, phosphate-buffered saline; scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.